PARIS, November 16 /PRNewswire-FirstCall/ -- Sanofi-Aventis, a leading
pharmaceutical company headquartered in France, has confirmed Euro RSCG
Life as the global agency in charge of all communications for
Lovenox/Clexane, the no 1 product for thrombosis treatment, and for Lantus
and Apidra, market leading diabetes treatments. Sanofi-Aventis has also
amplified its partnership with Euro RSCG Life by awarding the agency the
responsibility of launching all communications programs for all new brands
in these two therapeutic domains.
Sanofi-Aventis has also awarded Euro RSCG C&O their Corporate
Communications account, including internal editorial programs and
The Havas Group emphasizes that this success is the fruit of real
international collaboration with all Euro RSCG Worldwide's teams in more
than 40 countries.
Sanofi-Aventis is Euro RSCG Worldwide's first global pharmaceutical
client and this appointment demonstrates a significant increase in activity
across the broad range of skills offered by Euro RSCG Worldwide-
advertising, corporate communications, media relations, medical
communication and interactive communication.
Havas (Euronext Paris: HAV.PA) is a global advertising and
communications services group. Headquartered in Paris, Havas operates
through its two worldwide networks, Euro RSCG Worldwide headquartered in
New York and Havas Media in Barcelona, and through Arnold Worldwide
Partners. A multicultural and decentralized Group, Havas is present in more
than 75 countries through its networks of agencies and contractual
affiliations. The Group offers a broad range of communications services,
including traditional advertising, direct marketing, media planning and
buying, corporate communications, sales promotion, design, human resources,
sports marketing, multimedia interactive communications and public
relations. Havas employs approximately 14,400 people.
Further information about Havas is available on the company's website:
The Sanofi-aventis Group is the world's 3rd largest pharmaceutical
company, ranking number 1 in Europe. Backed by a world-class R&D
organization, Sanofi-Aventis is developing leading positions in seven major
therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes,
central nervous system, internal medicine, vaccines.
Havas: Anne Marsan
Euro RSCG Worldwide: Jonathan Sanchez